ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Predatory Journals Are Back in the Firing Line
Learn how to spot a predatory journal with these tips from PubsHub.
Overcoming Four Challenges to Successful Rare Disease Drug Development
Article relating to overcoming challenges to greatly improve the chances for a successful rare or “orphan” drug trial.
Why a Patient's Experience with a Drug Matters
Patient reported outcomes are often the primary endpoints in FDA approved pain drugs.
PRO Instruments to Improve Endpoints for Antibacterial Drug Trials
FDA's selection of ICON to validate PRO instruments used to access clinical endpoints in antibacterial drug trials.
Cell and Gene Therapies: On Course for Commercial Success?
Article on cell and gene therapies
Market Access 2017: A European Perspective
The article discusses how UK and European regulators’ market access plans for 2017 will affect the industry.
Medtech Needs Clinical Registries for Pre- and Postmarket Data
Insights on clinical registries and generating pre- and postmarket data.
Precision Medicine and Data Science
The future of drug development and the central role that precision medicine will play in global healthcare.
Real-world Evidence and the ‘Unsticking’ of Health Care Data
How Pharma and CROs must set high standards for acceptable real-world evidence research.
The Future of Clinical Trials
In this article Jennifer Byrne discusses the future of clinical trials.